UPL Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹12,269 Cr
verified against source
Revenue YoY
12%
reported change
EBITDA
₹2,434 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
UPL delivered a record Q3 FY26 with 12% revenue growth to ₹12,269 crore and 45% PAT growth to ₹452 crore, outperforming an already strong year-ago base. The beat was driven by 8% volume growth across all geographies—Latin America (+6%), Europe (+21%), India (+4%), and Rest of World (+32%)—along with 160bps contribution margin expansion to ~43%. EBITDA grew 13% to ₹2,434 crore with margins holding at healthy 20%. Balance sheet strengthening is notable: net debt/EBITDA improved from 3.8x to 2.5x, with $427 million debt reduction since Dec-24. Management maintained FY26 guidance of 4-8% revenue and 12-16% EBITDA growth, citing Q4 seasonality and US tariff uncertainties as headwinds. The Advanta IPO DRHP filing signals upcoming value unlock through deleveraging. Key risks include persistent pricing pressure in Brazil insecticides, ongoing US tariff costs (~$8M YTD EBITDA impact), and LATAM credit stress. Q4 visibility is supported by record US prepaid orders (+25% YoY) and new product traction in Brazil.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated guidance citing resilient YTD performance, strong Q3 momentum, and Q4 seasonal strength despite caution on US/LATAM uncertainties.
- Target range maintained with confidence from 22% EBITDA growth in 9M and margin expansion of 200bps YTD, though Q4 margins expected to be weighted toward volume-led growth.
- Target improvement from 2.1x at FY25 start, supported by operational cash generation (~$400M in Q4) and Advanta IPO proceeds for deleveraging.
- Guidance from Capital Markets Day maintained; Q3 NWC at 116 days reflects seasonal buildup ahead of Q4 being the largest sales quarter.
Risks flagged
- 50% tariffs on non-exempt imports continue to pressure margins; ~$30M net tariff impact expected in Q4 alone versus $8M YTD as strategies (bonded warehouses, technical vs formulated imports) have partial offset. Analyst raised concern; management acknowledged dynamic situation with uneven pricing across competitors.
- Premium brand Sperto faces intense competition with price erosion in Brazil sucking pest segment. Management noted premium brand pressure but sees Ferrosce traction and new insecticide launch (successor product) as mitigation.
- Liquidity stress on retailers/distributors in Latin America resulting in higher ECL provisioning (~$5M in Q3). Receivables days increased 15 days YoY due to credit terms pressure in LATAM and regional mix shift.
- On midpoint of guidance, Q4 implies only 2% revenue/EBITDA growth versus 12%/13% in Q3 and 8%/22% YTD. Management retained cautious outlook given Q4 last year was exceptionally strong (>=$1.8B) and ongoing US/LATAM uncertainties.
Key quotes
- Despite continued operational headwinds over the year, this was yet another record quarter for us with a strong performance delivered over a strong third quarter last year.
- We did purposely postpone some sales in Q3 in December in particular... The quantum of that business that we postponed would be in the range of $30 million.
- Prepaid dollars in the US was at a record high and increased by about 25% over the prepaid level of last year.
Research modules